Literature DB >> 3071463

The therapeutic dilemma of hypertension in the elderly.

S Julius1.   

Abstract

There are good reasons to treat hypertension in the elderly. Elevated blood pressure at any age increases morbidity and mortality from cardiovascular disease. Treatment trials suggest that antihypertensive treatment in the elderly decreases strokes, may improve the cardiovascular morbidity, but does not prolong life. Consequently, elevated blood pressure in people over 65 years of age should be treated, but there is no justification for an overly aggressive approach. Knowledge of side effects of various drugs and appreciation of a patient's specific features permit individual 'tailoring' of the treatment and optimise the outcome. No present-day antihypertensive drugs are specific for the elderly. The drive to combat cardiovascular morbidity and mortality in the elderly continues. New drugs are under development and promise to further improve results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3071463     DOI: 10.2165/00003495-198800361-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  Changes in cardiac output with age.

Authors:  M BRANDFONBRENER; M LANDOWNE; N W SHOCK
Journal:  Circulation       Date:  1955-10       Impact factor: 29.690

2.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

3.  Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study.

Authors:  J Wikstrand; G Westergren; G Berglund; D Bracchetti; A Van Couter; C A Feldstein; K S Ming; K Kuramoto; S Landahl; E Meaney
Journal:  JAMA       Date:  1986-03-14       Impact factor: 56.272

4.  Effects of age on ventricular performance during graded supine exercise.

Authors:  D L Mann; B S Denenberg; A K Gash; P T Makler; A A Bove
Journal:  Am Heart J       Date:  1986-01       Impact factor: 4.749

5.  Effect of age on the response of the left ventricular ejection fraction to exercise.

Authors:  S Port; F R Cobb; R E Coleman; R H Jones
Journal:  N Engl J Med       Date:  1980-11-13       Impact factor: 91.245

Review 6.  Aging and the cardiovascular system.

Authors:  A Amery; H Wasir; C Bulpitt; J Conway; R Fagard; P Lijnen; T Reybrouck
Journal:  Acta Cardiol       Date:  1978       Impact factor: 1.718

7.  Large arteries in hypertension: acute effects of a new calcium entry blocker, nitrendipine.

Authors:  J Levenson; A C Simon; M E Safar; J Bouthier; B C Maarek
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

Review 8.  Position of calcium antagonists in antihypertensive therapy.

Authors:  F R Bühler; P Bolli; P Erne; W Kiowski; F B Müller; U L Hulthén; B H Ji
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

Review 9.  Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.

Authors:  P Vanhoutte; A Amery; W Birkenhäger; A Breckenridge; F Bühler; A Distler; J Dormandy; A Doyle; E Frohlich; L Hansson
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

10.  A longitudinal study of urinary creatinine and creatinine clearance in normal subjects. Race, sex, and age differences.

Authors:  G D James; J E Sealey; M Alderman; S Ljungman; F B Mueller; M S Pecker; J H Laragh
Journal:  Am J Hypertens       Date:  1988-04       Impact factor: 2.689

View more
  2 in total

Review 1.  Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention.

Authors:  L G Spagnoli; A Mauriello; A Orlandi; G Sangiorgi; E Bonanno
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 2.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.